Lineage Cell Therapeutics Inc. — Director's Dealing 2021

Oct 12, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Lineage Cell Therapeutics, Inc. (LCTX)
CIK: 0000876343
Period of Report: 2021-09-30

Reporting Person: Culley Brian M (Director, President and CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-09-30	Common Shares, no par value	M	15450	—	Acquired	71266	Direct
2021-09-30	Common Shares, no par value	F	5343	$2.52	Disposed	65923	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-09-30	Restricted Stock Units	$0.00	M	15450	Disposed		Common Shares (15450)	Direct

Footnotes

F1: Shares earned by the reporting person as a result of the vesting of a portion of restricted stock units ("RSUs") granted to the reporting person on September 17, 2018. Upon settlement, RSUs convert into common shares of the issuer on a one-for-one basis.

F2: Does not include common shares of the issuer that may be acquired upon settlement of RSUs that have not vested as of the date of this filing or upon the exercise of stock options outstanding as of the date of this filing.

F3: Shares withheld by the issuer to satisfy statutory tax withholding requirements on the vesting of 15,450 RSUs in a transaction exempt under Rule 16(b)-3. No shares were sold in connection with this transaction.

F4: The reporting person was granted RSUs on September 17, 2018, that vested with respect to 25% of the shares subject to the award on September 17, 2019, and the balance vest in 12 equal quarterly installments at the end of each quarter thereafter.